Stockreport

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date [Read more]